Skip to main content

FDA News

Featured Article
The FDA has issued a Class II recall for a anxiolytic used to treat anxiety.
Boehringer Ingelheim Pharmaceuticals Inc is recalling 15,198 bottles of Micardis tablets because the drug is subpotent.


Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means for…
Tony Lin, PharmD, senior scientific director, AbbVie US medical affairs, discusses the VIALE-A and VIALE-C trials, which helped determine the approval of Venclexta for acute myeloid leukemia, and highlights what this approval means for clinical…
Michael Cawley, PharmD, discusses the recent news from the FDA on benzodiazepines, which includes new boxed warnings for the use of these medications, and changes to the prescribing information and patient medication guides.
A Class II recall is active for a prescription analgesic injection used during anesthetic periods, premedication, induction and maintenance, and in the immediate postoperative period.

Interactive Features

In this episode of PopHealth Perspectives, Kiersten Combs, vice president, US Cardiovascular and Metabolic Disease (US CVMD) and Naeem Khan, MD, vice president, medical, US CVMD, AstraZeneca, discuss the recent approval of Farxiga (dapagliflozin),…
Saad Usmani, MD, discusses the recent approval of daratumumab subcutaneous formulation for patients with multiple myeloma, and explains the major benefits of this treatment for this patient population.
In this podcast, Andree Amelsberg, vice president of US Medical Affairs Oncology and Hematology at Janssen, and Danelle James, Imbruvica clinical science lead at Pharmacyclics LLC, an AbbVie company, discuss the recent expanded approval of Imbruvica…
Which narcotic pain medication—used to treat moderate to severe pain—has been recalled in the last two FDA Enforcement Reports?
Back to Top